{"transactions":[{"id":2449832,"issuer":{"id":88837,"kind":"organization","name":"Astra Space, Inc.","symbol":"ASTR"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-01-04T17:15:21.000Z","date":"2021-12-31","kind":"other","acquired":false,"shares":4200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 31, 2021, Canaan X L.P. (the \"Canaan Fund\") distributed, for no consideration, 4,200,000 shares of Class A Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners X LLC (\"Canaan X\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the Shares held by the Canaan Fund.  On the same date, Canaan X distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 31, 2021, Canaan X L.P. (the \"Canaan Fund\") distributed, for no consideration, 4,200,000 shares of Class A Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners X LLC (\"Canaan X\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the Shares held by the Canaan Fund.  On the same date, Canaan X distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These reported securities are held directly by the Canaan Fund.  Canaan X is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":16489668,"source":{"system":"sec-edgar","filing":"0000899243-22-000544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814329/000089924322000544/doc4.xml","form_type":"4"}},{"id":3304138,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.500% Exchangeable Senior Subordinated Note due 2025","published_at":"2020-01-23T17:21:01.000Z","date":"2020-01-21","kind":"grant","acquired":true,"price":2000000,"reported_value":2000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time.  The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(continued from footnote 1) principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time.  The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"This Exchangeable Note is held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Canaan Fund.  Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Company's board of directors.  Investment and voting decisions with respect to the securities held by the Canaan Fund are made by the managers of Canaan X, collectively.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein."}],"derivative":{"expiration_date":"2025-01-31","underlying":"Ordinary Shares","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0000899243-20-001851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924320001851/doc4.xml","form_type":"4"}},{"id":3510350,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-05-28T16:55:03.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":602549,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":602549},"source":{"system":"sec-edgar","filing":"0001567619-19-012237","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000156761919012237/doc1.xml","form_type":"4"}},{"id":3510349,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-05-28T16:55:03.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":1658164,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1658164},"source":{"system":"sec-edgar","filing":"0001567619-19-012237","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000156761919012237/doc1.xml","form_type":"4"}},{"id":3510348,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-28T16:55:03.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":400000,"price":10,"value":4000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2660713,"source":{"system":"sec-edgar","filing":"0001567619-19-012237","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000156761919012237/doc1.xml","form_type":"4"}},{"id":3510347,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-28T16:55:03.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":602549,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement."},{"field":"shares","element":"transactionShares","label":"F4","text":"Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2260713,"source":{"system":"sec-edgar","filing":"0001567619-19-012237","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000156761919012237/doc1.xml","form_type":"4"}},{"id":3510346,"issuer":{"id":4069,"kind":"organization","name":"IDEAYA Biosciences, Inc.","symbol":"IDYA"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-28T16:55:03.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":1658164,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reported securities are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":1658164,"source":{"system":"sec-edgar","filing":"0001567619-19-012237","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000156761919012237/doc1.xml","form_type":"4"}},{"id":3529946,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":2296605,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":285867},"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3529945,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":5861455,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":729599},"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3529944,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":5970000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":743110},"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3529943,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3582000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":445866},"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3529942,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":50000,"price":15,"value":750000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2254442,"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3529941,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":285867,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2204442,"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3529940,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":729599,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":1918575,"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3529939,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":743110,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":1188976,"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3529938,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:15.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":445866,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":445866,"source":{"system":"sec-edgar","filing":"0001123292-19-000749","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000112329219000749/edgar.xml","form_type":"4"}},{"id":3914190,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Shares","published_at":"2018-05-30T17:25:12.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":229660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":229660},"source":{"system":"sec-edgar","filing":"0001209191-18-034203","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000120919118034203/doc4.xml","form_type":"4"}},{"id":3914189,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Shares","published_at":"2018-05-30T17:25:12.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":275446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":275446},"source":{"system":"sec-edgar","filing":"0001209191-18-034203","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000120919118034203/doc4.xml","form_type":"4"}},{"id":3914188,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2018-05-30T17:25:12.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":721408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":721408},"source":{"system":"sec-edgar","filing":"0001209191-18-034203","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000120919118034203/doc4.xml","form_type":"4"}},{"id":3914187,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T17:25:12.000Z","date":"2018-05-30","kind":"purchase","acquired":true,"shares":506656,"price":13,"value":6586528.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein."}],"balance_after":1733170,"source":{"system":"sec-edgar","filing":"0001209191-18-034203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000120919118034203/doc4.xml","form_type":"4"}},{"id":3914186,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T17:25:12.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":229660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein."}],"balance_after":1226514,"source":{"system":"sec-edgar","filing":"0001209191-18-034203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000120919118034203/doc4.xml","form_type":"4"}},{"id":3914185,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T17:25:12.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":275446,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein."}],"balance_after":996854,"source":{"system":"sec-edgar","filing":"0001209191-18-034203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000120919118034203/doc4.xml","form_type":"4"}},{"id":3914184,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T17:25:12.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":721408,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\"). The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein."}],"balance_after":721408,"source":{"system":"sec-edgar","filing":"0001209191-18-034203","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000120919118034203/doc4.xml","form_type":"4"}},{"id":3924089,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-21T16:34:24.000Z","date":"2018-05-17","kind":"sale","acquired":false,"shares":38968,"price":6.0911,"value":237357.9848,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $5.90 - $6.46, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2116552,"source":{"system":"sec-edgar","filing":"0000899243-18-013571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318013571/doc4.xml","form_type":"4"}},{"id":3930948,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-16T17:16:44.000Z","date":"2018-05-16","kind":"sale","acquired":false,"shares":29441,"price":6.456,"value":190071.096,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $6.45 - $6.50, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2155520,"source":{"system":"sec-edgar","filing":"0000899243-18-013082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318013082/doc4.xml","form_type":"4"}},{"id":3930947,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-16T17:16:44.000Z","date":"2018-05-15","kind":"sale","acquired":false,"shares":57715,"price":6.4815,"value":374079.7725,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $6.45 - $6.605, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2184961,"source":{"system":"sec-edgar","filing":"0000899243-18-013082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318013082/doc4.xml","form_type":"4"}},{"id":3930946,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-16T17:16:44.000Z","date":"2018-05-14","kind":"sale","acquired":false,"shares":77591,"price":6.3696,"value":494223.6336,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $6.25 - $6.69, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2242676,"source":{"system":"sec-edgar","filing":"0000899243-18-013082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318013082/doc4.xml","form_type":"4"}},{"id":3983055,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-26T16:25:19.000Z","date":"2018-03-23","kind":"sale","acquired":false,"shares":59950,"price":20.706,"value":1241324.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.50 - $21.26, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2320267,"source":{"system":"sec-edgar","filing":"0000899243-18-008487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318008487/doc4.xml","form_type":"4"}},{"id":3985131,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-22T17:33:28.000Z","date":"2018-03-22","kind":"sale","acquired":false,"shares":4759,"price":20.6205,"value":98132.9595,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.50 - $20.87, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2380217,"source":{"system":"sec-edgar","filing":"0000899243-18-008349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318008349/doc4.xml","form_type":"4"}},{"id":3985130,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-22T17:33:28.000Z","date":"2018-03-21","kind":"sale","acquired":false,"shares":17699,"price":20.6072,"value":364726.8328,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.50 - $20.79, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2384976,"source":{"system":"sec-edgar","filing":"0000899243-18-008349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318008349/doc4.xml","form_type":"4"}},{"id":3985129,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-22T17:33:28.000Z","date":"2018-03-20","kind":"sale","acquired":false,"shares":17060,"price":20.606,"value":351538.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.50 - $20.84, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2402675,"source":{"system":"sec-edgar","filing":"0000899243-18-008349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318008349/doc4.xml","form_type":"4"}},{"id":3989769,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-19T17:22:23.000Z","date":"2018-03-19","kind":"sale","acquired":false,"shares":13439,"price":20.5704,"value":276445.6056,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.50 - $20.755, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2419735,"source":{"system":"sec-edgar","filing":"0000899243-18-007980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318007980/doc4.xml","form_type":"4"}},{"id":3989768,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-19T17:22:23.000Z","date":"2018-03-16","kind":"sale","acquired":false,"shares":6926,"price":20.5115,"value":142062.649,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.50 - $20.60, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2433174,"source":{"system":"sec-edgar","filing":"0000899243-18-007980","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318007980/doc4.xml","form_type":"4"}},{"id":3994715,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-15T16:55:57.000Z","date":"2018-03-15","kind":"sale","acquired":false,"shares":11751,"price":20.6383,"value":242520.6633,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.50 - $20.91, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2440100,"source":{"system":"sec-edgar","filing":"0000899243-18-007581","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318007581/doc4.xml","form_type":"4"}},{"id":3994714,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-15T16:55:57.000Z","date":"2018-03-14","kind":"sale","acquired":false,"shares":200,"price":20.77,"value":4154.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2451851,"source":{"system":"sec-edgar","filing":"0000899243-18-007581","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318007581/doc4.xml","form_type":"4"}},{"id":3994713,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":131726,"kind":"organization","name":"CANAAN X L.P.","position":1,"cik":"0001619859","reported_name":"CANAAN X L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":105075,"kind":"organization","name":"Canaan Partners X LLC","position":2,"cik":"0001673228","reported_name":"Canaan Partners X LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-15T16:55:57.000Z","date":"2018-03-13","kind":"sale","acquired":false,"shares":1204,"price":20.842,"value":25093.768,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.77 - $21.045, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan X L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners X LLC (\"Canaan X\", and together with the Canaan Fund, the \"Canaan Entities\"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2452051,"source":{"system":"sec-edgar","filing":"0000899243-18-007581","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673228/000089924318007581/doc4.xml","form_type":"4"}}]}